Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Fragile X syndrome
Other

Fragile X syndrome

Tracked across 1 events · 6 articles · First seen Jun 10, 2026 · Last active Jun 10, 2026

Sentiment
50
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 50
Tech
CONNECTA_Therapeutics Initiates CTH120 Phase IIa Trial
CONNECTA Therapeutics>>>, a clinical-stage biotech company, announced the initiation of its Phase IIa clinical trial for CTH120, a first-in-class neuroplasticity modulator, in adult males with Fragile X syndrome>>>. This study builds on positive Phase I…
Impact: Fragile X syndrome>>> is the target condition for CTH120>>>'s clinical trial, representing a significant unmet medical need with no approved targeted therapies.
Jun 10, 2026 · 6 articles
NEWSDESK
Track Fragile X syndrome live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.